The international and prestigious scientific journal Frontiers in Oncology, on Friday 21 January 2022 published an article with the results of the research entitled:
"The effect of dietary intervention with high content of oleocanthal and oleacin olive oil in patients with early-stage Chronic Lymphocytic Leukaemia (CLL): A pilot randomised trial"
The experimental study was conducted with 22 patients who were diagnosed with early stage Chronic Lymphocytic Leukaemia (CLL) and who were under medical supervision and not receiving any treatment. One of the main objectives was to investigate the hypothesis that the anti-cancer biological effect of olive oil is related to its content of specific phenolic compounds and in particular oleocanthal and oleacin. It is the first time that the scientific community has been able to demonstrate that the oral administration of a daily dose of 25 mg of oleocanthal and oleacin through the consumption of 40 ml of extra virgin olive oil for a period of six months could be beneficial for CLL patients, reducing their white blood cell count, inducing the apoptosis of their cancer cells and improving their metabolism.
For this study, the following collaborated: Dr. Prokopis Magiatis and Dr. Eleni Melliou from the National and Kapodistrian University of Athens and the World Olive Center for Health (WOCH), Dr. Andrea Paola Rojas from the University of Peloponnese, Dr. I. Kontonis from the Hospital of Laconia, Dr. T. Nomikos from the Harokopio University and their colleagues A. Ioannidis, I. Dimopoulos, G. Kosmidis, M. Katsas. The extra virgin olive oil selected and administered to the patients was "The Governor- Premium extra virgin Olive Oil" from the Lianolia variety of Corfu, of the family Dafnis from the Olive Fabrica Company. The olive oil was selected among hundreds of other samples after being analyzed by Quantitative Nuclear Magnetic Resonance (qNMR) method. The qNMR method was developed in 2012 by professors Dr. Prokopis Magiatis, Dr. Eleni Melliou and their scientific team at the NKUA.
The study was funded by the non-profit organisation World Olive Oil Center for Health (www.worldolivecenter.com) with income derived entirely from membership fees, olive oil analysis and private donations. Upon completion of the study we can only feel joy and satisfaction for the encouraging results that demonstrate the need for an even larger and multicentre clinical trial and prove once again the high nutritional value of extra virgin olive oil but above all the catalytic effect on the human body of the use of Highly Phenolic Extra Virgin Olive Oil, making it a "superfood". Research and Production compose the blend of success but above all the picture of the future. A future where researchers and producers will work together shaping the best practices to produce quality products designed to promote consumers’ health.
The first clinical study with the administration of high phenolic extra virgin olive oil to patients with Chronic Lymphocytic Leukaemia and the publication of the results in an international scientific journal is a historic event. Another great step in the exploration of the magical world of olive oil but at the same time a great legacy. Let us continue to produce with a sense of responsibility!